ORAL AND INTRAVENOUS GANCICLOVIR FOR CYTOMEGALOVIRUS RETINITIS IN HIV INFECTION

口服和静脉注射更昔洛韦治疗 HIV 感染引起的巨细胞病毒性视网膜炎

• 批准号: 6113868
• 负责人: Charles Michael van der Horst
• 金额: $ 1.58万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6113868
• 关键词: AIDS education /prevention; AIDS therapy; HIV infections; antiAIDS agent; antiviral agents; clinical research; cytomegalovirus; drug administration rate /duration; ganciclovir; human subject; human therapy evaluation; intravenous administration; microorganism disease chemotherapy; opportunistic infections; oral administration; pathologic process; retinitis

To develop a non-event-driven therapeutic regimen in patients with AIDS- related first episode CMV retinitis. This means that one does not depend on disease progression as a trigger for changes in drug therapy but rather preemptively gives high doses of ganciclovir at regular intervals to prevent the common occurrence of early progression. In addition this protocl will attempt to define the best role for oral ganciclovir in maintenance therapy.

为艾滋病患者开发非事件驱动的治疗方案 相关的首发巨细胞病毒视网膜炎。 这意味着一个人不 取决于疾病进展作为药物治疗变化的触发因素 而是预先定期给予高剂量的更昔洛韦 间隔时间以防止早期进展的常见发生。 在 此外，该协议将尝试定义口头的最佳作用 更昔洛韦维持治疗。